GlassScriptPhysician profile
John P Greving
NPI 1043388036
$1,735.27
in general payments reported to CMS, 2019-2025
27 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2021: $132 · 2022: $219 · 2023: $311 · 2024: $381 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $290.08 | 2019-2025 | Repatha, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $151.45 | 2019-2024 | |
| Novo Nordisk INC | $149.14 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $120.88 | 2019-2025 | Zepbound, Mounjaro, Trulicity |
| Pfizer INC. | $113.95 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $104.96 | 2023-2025 | Rexulti, Abilify Maintena |
| Glaxosmithkline, LLC. | $86.69 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $75.26 | 2024-2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $68.77 | 2022-2025 | |
| Abbvie INC. | $67.99 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $55.90 | 2024-2025 | Airsupra, Breztri |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.61 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.79 | 2023 | Jardiance |
| Merck Sharp & Dohme LLC | $41.45 | 2024-2025 | Capvaxive, Gardasil 9 |
| Lundbeck LLC | $40.76 | 2019-2025 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $39.54 | 2019-2022 | |
| Verona Pharma, INC. | $32.92 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $29.06 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $27.73 | 2023 | Austedo Xr |
| Sanofi Pasteur INC. | $23.37 | 2025 | |
| Globus Medical, INC. | $21.37 | 2025 | Senza |
| Dexcom, INC. | $18.41 | 2024 | Dexcom G6 Transmitter |
| Resmed Corp | $17.13 | 2024 | |
| Ardelyx, INC. | $17.04 | 2024 | Ibsrela |
| Janssen Pharmaceuticals, INC | $16.31 | 2019 | |
| Exact Sciences Corporation | $15.60 | 2023 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.11 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Greving listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.